Edgestream Partners L.P. Has $3.09 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Edgestream Partners L.P. grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 228.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 46,286 shares of the company’s stock after buying an additional 32,202 shares during the quarter. Edgestream Partners L.P.’s holdings in Moderna were worth $3,093,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRNA. International Assets Investment Management LLC increased its stake in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after buying an additional 316,552 shares in the last quarter. State of Michigan Retirement System increased its stake in shares of Moderna by 201.9% in the second quarter. State of Michigan Retirement System now owns 274,248 shares of the company’s stock valued at $32,567,000 after buying an additional 183,407 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after acquiring an additional 167,596 shares during the last quarter. Finally, Citigroup Inc. boosted its holdings in Moderna by 30.5% in the third quarter. Citigroup Inc. now owns 591,910 shares of the company’s stock valued at $39,557,000 after acquiring an additional 138,378 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MRNA. Jefferies Financial Group decreased their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. JPMorgan Chase & Co. decreased their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a report on Tuesday, November 26th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and decreased their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Finally, Wolfe Research started coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $83.33.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have sold 1,147 shares of company stock valued at $76,245. 15.70% of the stock is owned by insiders.

Moderna Trading Down 0.8 %

NASDAQ MRNA opened at $43.06 on Monday. The stock’s 50-day moving average is $52.38 and its 200-day moving average is $90.84. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47. The firm has a market cap of $16.57 billion, a P/E ratio of -7.40 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the firm earned ($1.39) EPS. Moderna’s revenue for the quarter was up 3.8% compared to the same quarter last year. Sell-side analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.